Company Encyclopedia
View More
name
XOMA Royalty
XOMA.US
XOMA Royalty Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets. It has a portfolio with various assets.
1.945 T
XOMA.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
B
BiotechnologyIndustry
Industry Ranking41/394
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreA
    • ROE11.42%B
    • Profit Margin45.94%A
    • Gross Margin99.26%A
  • Growth ScoreA
    • Revenue YoY118.02%A
    • Net Profit YoY127.82%A
    • Total Assets YoY17.83%A
    • Net Assets YoY27.29%A
  • Cash ScoreB
    • Cash Flow Margin477.94%C
    • OCF YoY118.02%A
  • Operating ScoreD
    • Turnover0.19D
  • Debt ScoreD
    • Gearing Ratio58.98%D

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    XOMA Royalty Announces Closing of Transaction to Acquire Mural Oncology plc

    XOMA Royalty Corporation has completed its acquisition of Mural Oncology plc, sanctioned by the Irish High Court. Mural shareholders received $2.035 per share, and Mural's shares will be delisted from Nasdaq. Legal and financial advisors were involved in the transaction. XOMA Royalty, a biotech royalty aggregator, aims to improve human health by acquiring future economics of therapeutic candidates.

    fidelity·
    US
    MURA
    0.00%
    US
    XOMA
    -3.90%
    fidelity·
    US
    MURA
    0.00%
    US
    XOMA
    -3.90%

    Mural Oncology Announces Effectiveness of Scheme of Arrangement and Completion of Acquisition | MURA Stock News

    Mural Oncology plc announced the effectiveness of its scheme of arrangement, leading to its acquisition by XRA 5 Corp., a subsidiary of XOMA Royalty Corporation. The acquisition involves the entire issued share capital of Mural. The distribution of cash consideration to shareholders is expected to commence soon, with completion by December 19, 2025. Mural's shares have been delisted from the Nasdaq Global Market as of December 4, 2025. Forward-looking statements caution about potential risks and uncertainties.

    StockTitan·
    US
    MURA
    0.00%
    StockTitan·
    US
    MURA
    0.00%

    Xoma Q3 Operating Income SEK 0.3 Mln

    Xoma Ab :Q3 OPERATING INCOME AMOUNTED TO 0.325 MSEKQ3 EBITDA AMOUNTED TO -2.295 MSEKQ3 EBIT -2,329 (-1,278) MSEK

    Reuters·
    US
    XOMA
    -3.90%
    Reuters·
    US
    XOMA
    -3.90%

    Mural Oncology Sets Final Cash Consideration at $2.035 Per Share in XOMA Royalty Acquisition

    XOMA Royalty, through its subsidiary, is set to acquire Mural Oncology plc for $2.035 per share. The acquisition, announced on August 20, 2025, is expected to close in December 2025, pending Irish High Court approval and other conditions. Details are available on Mural Oncology's website. This news was generated by Public Technologies using AI and is for informational purposes only.

    Reuters·
    US
    XOMA
    -3.90%
    US
    MURA
    0.00%
    Reuters·
    US
    XOMA
    -3.90%
    US
    MURA
    0.00%

    XOMA Royalty Closes Acquisition of LAVA Therapeutics

    XOMA Royalty Corporation has completed its acquisition of LAVA Therapeutics, acquiring all outstanding shares. LAVA shareholders received $1.04 per share and a contingent value right (CVR) for future cash payments. XOMA now owns 100% of LAVA's successor, and LAVA shares will be delisted from Nasdaq. This news was generated by Public Technologies using AI and is for informational purposes only.

    Reuters·
    US
    XOMA
    -3.90%
    Reuters·
    US
    XOMA
    -3.90%
    © 2025 Longbridge｜Disclaimer